Literature DB >> 1580115

Ascites as a presenting feature of relapsed multiple myeloma. Report of a case diagnosed by aspiration cytology.

M Khoddami1, F N Esphehani, F S Aslani.   

Abstract

A 68-year-old woman with IgG-type multiple myeloma (MM) in remission and a chief complaint of ascites was found to have peritoneal fluid involvement by myeloma cells on cytologic study. There are only a few reports describing the cytologic features in patients presenting with ascites as the first manifestation of relapsed MM. IgG myeloma, however, is one of the rarest types. The patient had had pancreatic involvement months before her presentation with ascites, which itself is a rare manifestation of relapsed MM. Cytologic smears of ascitic fluid showed isolated and incoherent groups of cells with plasmacytoid features. To recognize myeloma as a cause of ascites is important because it may respond well to therapy. Aspiration cytologic study can be considered a useful method for follow-up and diagnosis of MM relapse even without a biopsy.

Entities:  

Mesh:

Year:  1992        PMID: 1580115

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  3 in total

1.  Multiple myeloma involving the porta hepatis and peritoneum causing biliary obstruction and malignant ascites.

Authors:  Augustin Attwell; Elizabeth Dee; Paul Russ; Russell Nash; Raj Shah
Journal:  Dig Dis Sci       Date:  2005-06       Impact factor: 3.199

2.  IgG Lambda Myeloma Presenting as Plasmacytic Ascites: Case Report and Review of Literature.

Authors:  Subhashis Mitra; Sanghamitra Mukherjee; Hema Chakraborty; Maitreyee Bhattacharyya
Journal:  Indian J Hematol Blood Transfus       Date:  2014-09-03       Impact factor: 0.900

3.  Refractory ascites as a presenting feature of extramedullary plasmacytoma in an end-stage renal disease patient with HIV infection.

Authors:  Karim Soliman; Johann Herberth; Tibor Fülöp; Angie Duong; Rachel L Sturdivant
Journal:  Clin Nephrol Case Stud       Date:  2019-02-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.